Bexobrutideg Shows Strong Phase 1 Results in WM Trial
BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational...
ASH 2025
Advertisement
Omisirge Delivers Breakthrough Outcomes for Severe Aplastic Anemia
DUBLIN, IRELAND & LONDON, UK — December 8, 2025 — Ayrmid Ltd., parent company of Gamida Cell Inc., announced...
Editas Medicine Advances Gene-Editing Therapy EDIT-401
Cambridge, Massachusetts – September 2, 2025 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene-editing biotechnology company, has nominated EDIT-401,...
Sumitomo Pharma Unveils Promising Data in Blood Cancers
Marlborough, Massachusetts – November 3, 2025 Sumitomo Pharma America, Inc. (SMPA) announced compelling new investigational data from multiple clinical...
BioNTech Advances Oncology Pipeline and Strengthens 2025 Financial Outlook
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
Advertisements
Aptose to Present Promising Tuspetinib AML Data at 2025 ASH Meeting
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
Advertisement
